Quadrature Capital Ltd Buys New Position in Cardlytics, Inc. (NASDAQ:CDLX)

Quadrature Capital Ltd bought a new stake in shares of Cardlytics, Inc. (NASDAQ:CDLX) during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 131,617 shares of the company’s stock, valued at approximately $1,906,000. Quadrature Capital Ltd owned approximately 0.27% of Cardlytics at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also added to or reduced their stakes in CDLX. Tower Research Capital LLC TRC boosted its holdings in Cardlytics by 349.3% in the fourth quarter. Tower Research Capital LLC TRC now owns 9,602 shares of the company’s stock worth $88,000 after acquiring an additional 7,465 shares in the last quarter. SG Americas Securities LLC raised its stake in shares of Cardlytics by 34.3% in the fourth quarter. SG Americas Securities LLC now owns 21,461 shares of the company’s stock worth $198,000 after purchasing an additional 5,484 shares during the last quarter. Clear Street Markets LLC purchased a new stake in shares of Cardlytics in the fourth quarter worth approximately $199,000. Banco Santander S.A. purchased a new stake in shares of Cardlytics in the first quarter worth approximately $199,000. Finally, Check Capital Management Inc. CA raised its stake in shares of Cardlytics by 14.0% in the fourth quarter. Check Capital Management Inc. CA now owns 23,200 shares of the company’s stock worth $214,000 after purchasing an additional 2,850 shares during the last quarter. Institutional investors own 68.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently commented on CDLX shares. Northland Securities started coverage on Cardlytics in a research note on Tuesday, June 18th. They issued an “outperform” rating and a $14.00 price objective for the company. Bank of America reaffirmed a “neutral” rating and set a $11.00 price target on shares of Cardlytics in a research report on Thursday, June 20th. Needham & Company LLC reaffirmed a “buy” rating and set a $12.00 price target on shares of Cardlytics in a research report on Tuesday, June 11th. Craig Hallum decreased their price target on Cardlytics from $18.00 to $12.00 and set a “buy” rating for the company in a research report on Thursday, May 9th. Finally, Northland Capmk raised Cardlytics to a “strong-buy” rating in a research report on Tuesday, June 18th. Two research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Cardlytics has an average rating of “Moderate Buy” and a consensus price target of $12.67.

Cardlytics Stock Performance

Shares of Cardlytics stock traded up $0.46 during trading hours on Friday, reaching $8.83. The company had a trading volume of 358,823 shares, compared to its average volume of 612,111. Cardlytics, Inc. has a one year low of $5.71 and a one year high of $20.52. The business has a fifty day simple moving average of $8.61 and a 200 day simple moving average of $9.52. The company has a debt-to-equity ratio of 1.30, a current ratio of 2.13 and a quick ratio of 2.13.

Cardlytics (NASDAQ:CDLX) last posted its quarterly earnings results on Wednesday, May 8th. The company reported ($0.35) EPS for the quarter. Cardlytics had a negative return on equity of 25.36% and a negative net margin of 55.23%. The company had revenue of $67.61 million during the quarter. Research analysts anticipate that Cardlytics, Inc. will post -1.8 earnings per share for the current fiscal year.

Insider Activity at Cardlytics

In other Cardlytics news, major shareholder Clifford Sosin acquired 225,000 shares of the company’s stock in a transaction that occurred on Thursday, May 9th. The stock was bought at an average price of $8.73 per share, with a total value of $1,964,250.00. Following the completion of the purchase, the insider now owns 6,361,113 shares of the company’s stock, valued at $55,532,516.49. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other Cardlytics news, CEO Karim Saad Temsamani sold 43,129 shares of Cardlytics stock in a transaction dated Tuesday, June 4th. The stock was sold at an average price of $8.65, for a total transaction of $373,065.85. Following the completion of the sale, the chief executive officer now owns 385,530 shares of the company’s stock, valued at $3,334,834.50. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, major shareholder Clifford Sosin purchased 225,000 shares of the company’s stock in a transaction on Thursday, May 9th. The shares were purchased at an average cost of $8.73 per share, with a total value of $1,964,250.00. Following the purchase, the insider now owns 6,361,113 shares of the company’s stock, valued at $55,532,516.49. The disclosure for this purchase can be found here. Over the last quarter, insiders sold 86,742 shares of company stock valued at $735,905. Company insiders own 4.40% of the company’s stock.

Cardlytics Company Profile

Cardlytics, Inc operates an advertising platform in the United States and the United Kingdom. It offers Cardlytics platform, a proprietary native bank advertising channel that enables marketers to reach customers through their network of financial institution partners through digital channels, such as online, mobile applications, email, and various real-time notifications; and Bridg platform, a customer data platform which utilizes point-of-sale data and enables marketers to perform analytics and targeted loyalty marketing, as well as measure the impact of their marketing.